50% Hemolysis Sensitivity Determination (CH50 Assay): Principles, Methods, and Applications

The 50% hemolysis sensitivity determination, best known as the CH50 assay, is the reference functional test for measuring total complement activity in serum and other biological matrices. By identifying the serum dilution that lyses 50% of antibody-sensitized sheep erythrocytes, the method provides a sensitive and reproducible readout of classical complement pathway integrity. This article outlines the scientific principle, sample requirements, test items, procedural workflow, quality controls, and practical applications of CH50 testing in clinical, pharmaceutical, and medical device laboratories.

Technical Overview

The 50% hemolysis sensitivity determination, commonly designated CH50 ("complement hemolysis 50"), is a quantitative functional bioassay that measures the total lytic capacity of the complement system in a sample. One CH50 unit is defined as the quantity, or reciprocal dilution, of complement-containing serum that lyses exactly 50% of a standardized suspension of antibody-sensitized sheep erythrocytes under strictly controlled conditions of temperature, ionic strength, calcium and magnesium concentration, cell concentration, and incubation time.

The analytical principle relies on the classical complement pathway. Sheep red blood cells (SRBC) are coated with rabbit anti-sheep erythrocyte antibody (hemolysin, or amboceptor), forming so-called EA complexes. Antibody Fc regions engage C1q and trigger the sequential activation cascade from C1 through C3 and C5, culminating in assembly of the membrane attack complex (C5b-9). Insertion of the terminal complex into the erythrocyte membrane causes colloid-osmotic lysis and release of hemoglobin, which is quantified spectrophotometrically at 540 to 541 nm. The amount of hemoglobin released is directly proportional to the degree of complement-mediated lysis.

The choice of the 50% endpoint is fundamental to the sensitivity of the method. The complement dose-hemolysis relationship follows a sigmoidal curve described by the von Krogh equation, in which the ratio of lysed to non-lysed cells, x/(1-x), is proportional to the complement concentration raised to a power n. At the midpoint of the curve, the slope is steepest, meaning that a minimal change in complement concentration produces the largest measurable change in hemolysis. Plotting log[x/(1-x)] against the log of serum volume or dilution linearizes the curve and allows precise interpolation of the 50% hemolysis point, from which the CH50 value in units per milliliter is calculated.

Results are reported as CH50 units per milliliter, with typical adult reference intervals in the range of approximately 26 to 55 U/mL or 50 to 100 CH50 U/mL depending on the procedural variant and calculator used by the laboratory. Testing is typically performed by accredited third-party laboratories following clinical laboratory standards guidance, with calibration traceable to international biological standards. In medical device and biomaterial contexts, complement-related evaluation is aligned with the hemocompatibility framework of ISO 10993-4 and its Chinese counterpart GB/T 16886.4.

Testing Samples

Human Serum

Venous blood is collected into plain tubes without anticoagulant, allowed to clot for 30 to 60 minutes, and centrifuged promptly, with serum separated within one to two hours of collection. Because complement proteins are heat labile, samples must be kept at 2 to 8 degrees Celsius during handling and frozen at minus 60 degrees Celsius or below for longer storage. Repeated freeze-thaw cycles, gross hemolysis, and delayed processing are the principal causes of falsely low results. EDTA or citrate plasma is not acceptable for classical pathway functional testing because chelation of calcium and magnesium ions blocks C1q binding and C3 convertase formation.

Animal Serum for Preclinical and Toxicology Studies

Serum from mice, rats, guinea pigs, rabbits, dogs, and non-human primates is frequently submitted for complement activity assessment in immunotoxicology programs. Guinea pig serum, historically the richest complement source, remains a common reference material, while rodent sera require species-validated assay conditions. The same cold-chain and anticoagulant restrictions apply to veterinary and animal study samples.

Biological Products and Formulation Samples

Intravenous immunoglobulin lots, monoclonal antibodies, liposomal and nanoparticle formulations, excipients, and process intermediates may be evaluated for their capacity to consume or activate complement. These submissions support lot release, comparability exercises, and risk assessment for infusion reactions such as complement activation-related pseudoallergy.

Reference Erythrocyte Suspensions and Reagents

Sheep erythrocytes preserved in Alsever solution and used within their stated shelf life, rabbit hemolysin of defined potency, and gelatin veronal-buffered saline containing calcium and magnesium ions are the core reagents. Cell suspensions are standardized photometrically, for example by adjusting the suspension so that complete lysis in water yields a defined optical density at 541 nm, ensuring lot-to-lot consistency.

Testing Items

Accredited third-party laboratories offering 50% hemolysis sensitivity determination typically cover the following test portfolio:

• Total hemolytic complement activity (CH50 or CH100), reflecting the global functional integrity of the classical and terminal pathways.
• Classical pathway activity, performed with antibody-sensitized sheep erythrocytes in calcium- and magnesium-containing veronal buffer.
• Alternative pathway activity (AP50 or AH50), performed with unsensitized rabbit erythrocytes in magnesium-EGTA buffer that blocks classical activation.
• Lectin pathway activity, assessed with specialized target cells or capture surfaces for mannose-binding lectin studies.
• Complement lysis sensitivity of erythrocytes, evaluating the intrinsic sensitivity of a patient's red cells to complement attack, historically applied in paroxysmal nocturnal hemoglobinuria workups.
• Reagent titration services, including potency assignment of complement lots and determination of the optimal sensitizing dose of hemolysin for serological platforms.

Because a normal CH50 requires intact function of C1q, C2, C4, C3, C5 through C9, and the control proteins, a near-absent CH50 indicates a deficiency or consumption of at least one classical or terminal component. Combining CH50 with AP50 and antigenic assays for C3 and C4 allows precise localization of the defective step in the cascade.

Testing Methods

Sample Collection and Pre-Analytical Handling

Specimens are logged, inspected for hemolysis and lipemia, and equilibrated on ice. Aliquots are prepared to avoid repeated freeze-thaw cycles, and heat-inactivated serum controls are included where method validation requires them. Chain-of-custody, collection time, and storage temperature records form part of the technical dossier.

Preparation and Sensitization of Sheep Erythrocytes

Sheep erythrocytes are washed three times in gelatin veronal-buffered saline and standardized photometrically. The cells are then incubated with an optimally titrated amount of rabbit hemolysin, typically corresponding to two to five minimal hemolytic units, at 37 degrees Celsius for 20 to 30 minutes with gentle mixing. After sensitization, the EA cells are washed and resuspended to the defined working concentration.

Serial Dilution and Hemolytic Reaction

Serial dilutions of the test serum are prepared in calcium- and magnesium-containing buffer. A fixed volume of standardized EA suspension is added to each dilution, and the mixtures are incubated at 37 degrees Celsius for 30 to 60 minutes. Each run includes a cell blank for zero percent lysis, a water or detergent tube for 100 percent lysis, a reagent blank, and a calibrated reference serum as a run control.

Spectrophotometric Measurement and Calculation

Following incubation, the reaction tubes are centrifuged and the optical density of the supernatants is read at 540 to 541 nm. The percentage of hemolysis for each dilution is calculated relative to the blank and total lysis controls. Results are plotted according to the von Krogh transformation, and the serum dilution corresponding to 50% hemolysis is interpolated from the linear portion of the curve. The reciprocal of this dilution, corrected for the dilution scheme, yields the CH50 value in units per milliliter. Samples are analyzed in duplicate, with acceptance criteria for replicate precision defined in the laboratory's validated procedure.

Quality Control and Standardization

Method performance is monitored using calibrator sera traceable to international biological standards, with Levey-Jennings trending of control results. Incubation temperature, timing, buffer composition, and erythrocyte standardization are validated and documented. Laboratories operating under recognized quality frameworks, such as ISO 15189-aligned management systems or clinical laboratory standards guidance, participate in external quality assessment schemes to verify ongoing comparability. For medical device submissions, complement-related data packages are prepared to be consistent with ISO 10993-4 and GB/T 16886.4 hemocompatibility expectations.

Applications

The 50% hemolysis sensitivity determination serves decision-making across clinical diagnostics, pharmaceutical development, and biomaterials evaluation. Representative applications include:

• Clinical immunology: screening for hereditary deficiencies of classical and terminal complement components, and monitoring complement consumption in systemic lupus erythematosus, immune-complex glomerulonephritis, cryoglobulinemia, and severe infections.
• Hematology: assessment of complement-mediated red cell destruction and evaluation of erythrocyte complement sensitivity in the diagnostic workup of paroxysmal nocturnal hemoglobinuria and autoimmune hemolytic anemia.
• Therapeutic drug monitoring: verifying functional complement blockade during anti-complement therapy, where effective terminal pathway inhibition drives CH50 activity to near-zero values.
• Pharmaceutical and nanomedicine development: screening biologics, liposomes, and nanoparticles for complement activation potential and infusion-reaction risk during formulation optimization.
• Medical devices and biomaterials: supporting hemocompatibility evaluation, in which complement activation is one of the recognized interaction categories under ISO 10993-4 and GB/T 16886.4, complementing split-product immunoassays such as C3a, C5a, Bb, C4d, and SC5b-9.
• Immunotoxicology: quantifying immunosuppressive or immunostimulative effects of test articles on complement function in rodent and larger animal studies.
• Serology and reagent standardization: assigning complement units for complement-fixation assays, complement-dependent cytotoxicity crossmatching, and vaccine potency methods that require complement of defined lytic activity.

FAQ

Why is the 50% hemolysis endpoint used instead of complete lysis?

The hemolytic dose-response curve is sigmoidal and flattens near total lysis, where large changes in complement produce negligible changes in hemolysis. At the 50% point the curve is steepest, so the smallest change in complement activity generates the largest measurable change in hemolysis. This is why the 50% endpoint, formalized in the von Krogh equation, delivers maximum analytical sensitivity and precision.

What do abnormal CH50 results indicate?

Low or absent CH50 suggests either a hereditary deficiency of a classical or terminal pathway component or acquired consumption by immune-complex disease, active glomerulonephritis, cryoglobulinemia, or overwhelming infection. Elevated CH50 is often observed in acute-phase inflammatory states. Interpretation is strengthened by combining CH50 with AP50 and antigenic C3 and C4 measurements.

Can plasma be tested instead of serum?

For classical pathway functional testing, no. EDTA and citrate chelate the calcium and magnesium ions essential for C1 activation and convertase stability, producing artifactually low or absent activity. Serum collected into plain tubes is the required matrix, whereas EDTA plasma is suitable only for antigenic complement marker assays.

How do CH50 and AP50 differ?

CH50 assesses the classical pathway using antibody-sensitized sheep erythrocytes in calcium- and magnesium-containing buffer, while AP50 assesses the alternative pathway using unsensitized rabbit erythrocytes in magnesium-EGTA buffer that selectively blocks classical activation. Running both assays distinguishes, for example, a C4 deficiency, which abolishes CH50 but preserves AP50, from a properdin or factor D deficiency, which shows the reverse pattern.

How sensitive is complement to sample handling errors?

Extremely sensitive. Complement activity declines rapidly at room temperature, is degraded by repeated freeze-thaw cycles, and is reduced by hemolyzed or improperly timed collections. Robust pre-analytical controls, including cold-chain management and rapid serum separation, are essential for reliable results.

What is the typical turnaround time?

The bench procedure, from erythrocyte sensitization through spectrophotometric calculation, generally requires three to four hours. Routine reporting by accredited third-party laboratories is commonly completed within one to three working days of sample receipt, with extended timelines for combined pathway panels or method development work.